Core Insights - BD (Becton, Dickinson and Company) is initiating a patient data registry for the Rotarex™ Atherectomy System to evaluate real-world outcomes for patients with peripheral artery disease (PAD) [1][2]. Group 1: Registry Details - The registry, named "XTRACT," is a prospective, multi-center, single-arm, post-market study aimed at assessing the clinical performance of the Rotarex™ Atherectomy System in treating U.S. patients with PAD lesions [3]. - The XTRACT Registry will enroll up to 600 patients across approximately 100 clinical sites in the United States, with the first patient expected to be enrolled later this year [3]. - Clinical follow-up evaluations will be conducted at 30 days, 6 months, and 12 months post-procedure to assess safety and effectiveness [3]. Group 2: Clinical Significance - The registry aims to provide valuable data to support clinical decision-making and enhance patient outcomes in managing PAD [4]. - The Rotarex™ Atherectomy System is designed to efficiently remove plaque and thrombus in peripheral arteries, serving dual purposes as both an atherectomy and thrombectomy device [4]. - The XTRACT Registry is the first comprehensive registry focused on real-world applications of the Rotarex™ System, highlighting BD's commitment to optimizing treatment strategies in collaboration with leading physicians [5]. Group 3: Industry Context - PAD affects over 21 million Americans and more than 200 million people globally, posing risks of cardiovascular complications and lower limb amputation [5]. - BD's initiative reflects its ongoing commitment to innovative technological development and evidence-based research to support physicians and improve patient outcomes [5].

Core Viewpoint - The article discusses the recent developments regarding the temporary final rule (IFR) issued by the U.S. government on January 16, 2025, which restricts the export of certain flow cytometers to China. The company, BD, is actively communicating with the U.S. government to seek revisions to this rule and has successfully obtained export licenses to continue serving its customers in China [1][3][5]. Summary by Sections - The U.S. government has approved BD's export license application, allowing the company to continue providing flow cytometers to its customers in China. This approval is seen as a positive step towards compliance with U.S. regulations [3][4][5]. - BD has received its first export license on April 18, 2025, which permits the sale, delivery, installation, and servicing of BD's spectral and 26+ channel flow cytometers in China. This license provides a clear path for BD to operate within the regulatory framework [1][3][4]. - The company is now officially restarting marketing efforts for several instruments in China, including the BD FACSDiscover™ S8 cell sorter and various models of the BD FACSymphony™ series, aiming to establish new collaborations [4][5].

Core Insights - The studies published in The Lancet Oncology and Cancer Medicine reveal that cancer patients are at a significantly higher risk of developing antimicrobial resistant (AMR) infections compared to non-cancer patients, highlighting the urgent need for improved infection control measures in this vulnerable population [1][2][4]. Study Findings - The studies are the first large, multi-center investigations quantifying AMR among cancer patients in the U.S., providing strong evidence that superbugs pose a substantial risk across various healthcare settings [2][6]. - AMR rates among key pathogens were found to be 1 to 3 times higher in outpatient cancer patients, with some specific pathogen-source combinations showing up to 5 times greater rates compared to non-cancer patients [6][8]. - Hospitalized cancer patients were found to be 1.5 to 2 times more likely to encounter AMR infections than their non-cancer counterparts [6][8]. Implications for Cancer Care - The emergence of AMR threatens the effectiveness of antibiotics, which are crucial for treating infections and preventing complications during cancer treatments such as chemotherapy and surgery [3][4]. - The findings suggest that the rapid rise of AMR could undermine new cancer therapies, including CAR T-cell therapy and other immunotherapies, due to the associated risks of immunosuppression and opportunistic infections [3][4]. Recommendations - The studies emphasize the need for enhanced infection prevention programs, focused antibiotic stewardship, and the increased use of rapid diagnostic tools to better manage AMR risks in cancer patients [4][6].

Company Overview - Becton, Dickinson and Company (BD) has launched the BD FACSDiscover A8 Cell Analyzer, integrating spectral flow cytometry with real-time cell imaging, enhancing cellular behavior insights [1][2] - The BD FACSDiscover A8 is the first platform to combine BD CellView Image Technology and BD SpectralFX Technology, allowing unprecedented clarity and precision in cell visualization and analysis [1][4] Product Impact - The launch of the BD FACSDiscover A8 is a significant advancement in BD's Biosciences segment, reinforcing its leadership in life sciences innovation [2][4] - The platform is expected to accelerate research in immunology, oncology, and biomedical fields by enabling real-time observation of complex cellular processes [2][4] Market Performance - Following the announcement, BD's shares remained flat, with a year-to-date decline of 22.7%, contrasting with the industry's growth of 0.9% and the S&P 500's gain of 0.7% [3] - BD currently holds a market capitalization of $50.27 billion and an earnings yield of 8.1%, surpassing the industry's 5.3% [5] Technological Features - The BD FACSDiscover A8 features high-resolution analysis of over 50 cellular characteristics, ideal for advanced applications like biomarker discovery [7][8] - It includes high-speed, real-time imaging capabilities, allowing detailed observation of cellular interactions and processes [8][9] - The platform supports translational research with high-throughput automation and user-friendly software workflows for large datasets [9][10] Industry Prospects - The global cell analysis market is projected to grow from $31.59 billion in 2024 at a CAGR of 10.03% from 2025 to 2030, driven by chronic disease prevalence and advancements in technologies [11][12] - The introduction of the FACSDiscover A8 is expected to significantly boost BD's business in this growing market [12]

Company Overview - Becton, Dickinson and Company is a nearly $22 billion company that has undergone significant transformations, including two large acquisitions of CareFusion and Bard [4]. Recent Developments - The company has successfully brought the Alaris product back to market and achieved a run rate, alongside making strategic portfolio adjustments such as the divestiture of its diabetes segment and the acquisition of the Edwards Critical Care business and Parata [3]. Financial Performance - Despite improvements in operational margins and strategic initiatives, the company's stock has declined, attributed to perceptions of slowed revenue growth [3].

Summary of Becton, Dickinson and Company (BDX) 2025 Conference Call Company Overview - **Company**: Becton, Dickinson and Company (BDX) - **Conference Date**: May 13, 2025 - **CEO**: Tom Poland Key Points Company Performance and Strategy - Over the past five years, BDX has transformed into a nearly $22 billion company, focusing on innovation and quality improvements [4][5] - The company has achieved a compound annual growth rate (CAGR) of approximately 5.6% in revenue since launching BD 2025 [5] - Current revenue growth is impacted by macroeconomic factors, including China's Value-Based Pricing (VBP) and life sciences funding constraints [5][6] Revenue Growth Challenges - Revenue growth has slowed, with a projected decline in China of high single digits to low double digits for the year [6][16] - Life sciences revenue growth was flat last year and is expected to decline in the low single digits this year due to research funding constraints [6][7] - The farm systems business, which previously saw 12% growth, is recovering after a flat performance last year [7][20] Q2 Performance and Guidance - Q2 growth was only 0.9%, significantly lower than the initial expectation of 2.75% [11][12] - Key factors for the decline included reduced NIH funding impacting instrument spending and increased VBP in China [12][13] - Full-year guidance was lowered by $200 million, reflecting the challenges in China, biosciences spending, and the ramp-up of Bactech [16][17] Actions Taken Post-Q2 - BDX has implemented several actions to address the challenges, including enhancing commercial excellence and increasing R&D investments [18][19] - The company is focusing on key growth catalysts such as PureWick and its peripheral vascular business [19][20] Margin and Cost Management - BDX has seen a gross margin expansion of 190 basis points, attributed to the BD Excellence initiative aimed at driving efficiency [24][25] - The company plans to continue investing in R&D and selling, with a focus on maintaining strong operating margins [24][26] Tariffs and Supply Chain Adjustments - The company is actively managing tariff impacts, with a focus on sourcing changes to mitigate costs [27][29] - Approximately 80% of U.S. revenue is derived from products manufactured domestically or tariff-exempt [32] Life Sciences Separation Update - The separation of the life sciences business is on track, with an announcement expected in summer 2025 [40][43] - The bioscience business is recognized for its innovative assets, including advancements in cancer research technology [41][42] Future Outlook - The RemainCo business is projected to maintain mid-single-digit growth, supported by strong market positions and recurring revenue from consumables [46][48] - BDX is focused on disciplined capital deployment, avoiding large transformational M&A, and prioritizing high-return investments [51][53] Conclusion - BDX is navigating a challenging macro environment while focusing on innovation, operational excellence, and strategic growth initiatives to enhance shareholder value [4][5][19]

Media: Troy Kirkpatrick VP, Public Relations 858.617.2361 [email protected] Investors: Adam Reiffe Sr. Director, Investor Relations 201.847.6927 [email protected] SOURCE BD (Becton, Dickinson and Company) BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions t ...

导读： BD宣布其首台国产流式细胞仪在中国获证，此举强化了其本地化能力，并为其诊断业务发展注入新动力。 特别提示 微信公众号机制调整，请点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 5月1 2日召开，ACCSI 2 0 2 5 •上海|第一届流式细胞仪产业化发展论坛一轮通知！ 5月1日，BD在其官方微信公众号宣布：旗下首台国产 流式细胞仪 ——BD FACSLy ri c正式在中国获证： 注册证编号：苏械注准2 0 2 5 2 2 2 0 7 4 8： ACCSI 2 0 2 5第一届流式细胞仪产业发展论坛 5月1日，全球医疗技术巨头BD（Be c t o n , Di c k i n s o n a n d Comp a n y）发布了2 0 2 5财年第二季度财报。2 0 2 5财年第二季度，BD营收5 2 . 7 2亿美 元，同比增长4 . 5%，其中有机增长为0 . 9%。依托"BD Ex c e ll e n c e "运营体系的持续推进，毛利率提升至5 4 . 9%，调整后每股收益达到3 . 3 5美 元，同比增长5 . 7%，超出市场预期。 ——会 ...

Core Viewpoint - Becton Dickinson has lowered its fiscal year 2025 guidance, reflecting challenges in organic revenue growth despite reporting adjusted earnings per share that exceeded expectations [1][2][4]. Financial Performance - The company reported adjusted earnings per share of $3.35 for the first quarter of fiscal 2025, an increase from $3.17 a year ago, beating the consensus estimate of $3.28 [1]. - First-quarter sales were $5.27 billion, representing a year-over-year increase of 4.5%, but fell short of the consensus estimate of $5.35 billion [1]. Guidance and Market Outlook - Becton Dickinson expects fiscal 2025 revenues to be between $21.8 billion and $21.9 billion, with updated organic revenue growth guidance of 3.0% to 3.5% [2]. - The company's previous guidance was $21.7 billion to $21.9 billion, indicating a slight improvement in the estimated impact of foreign currency [2]. Analyst Ratings and Market Reactions - Goldman Sachs downgraded Becton Dickinson from Buy to Neutral, reducing the price target from $256 to $192, citing a 25% decline in stock value since being added to the Buy list [3][8]. - William Blair also downgraded the stock to Market Perform, expressing disappointment with the fiscal second-quarter update and the lack of predictable revenue growth [6][8]. Growth Challenges - Analysts noted that Becton Dickinson's growth is closely tied to overall market growth, which has slowed, impacting the company's growth targets [5]. - The forward outlook for organic revenue growth has decreased from approximately 5-6% two years ago to around 3-4%, placing Becton Dickinson at the low end of the MedTech sector [4][5]. Future Catalysts - Analysts are looking for greater confidence in a reacceleration of organic growth, with fiscal 2026 guidance and updates on the separation of the Bioscience and Diagnostics business seen as key catalysts [7][8].

Group 1 - The article emphasizes the importance of actionable investment ideas for short-term market conditions, particularly in light of an upcoming two-week wedding vacation for the author [1] - The investing group "The Dividend Kings" focuses on high-quality dividend investments to help investors safeguard and grow their money across various market conditions [2] - The team of analysts associated with "The Dividend Kings" provides resources such as model portfolios, buy ideas, and company research reports to assist members in making informed investment decisions [2] Group 2 - The article includes a disclosure stating that past performance does not guarantee future results, highlighting the inherent uncertainties in investment outcomes [3] - It clarifies that no specific investment recommendations are being made, and opinions expressed may not represent the views of the entire platform [3] - The analysts contributing to the article may not be licensed or certified, indicating a diverse range of perspectives from both professional and individual investors [3]